A reflexion on a piece written for and published by OpenDemocracy in November 2010, shortly after the public release of the iPrEX trial. Three years later many of the questions raised then are still very much relevant. Of course we now know much more about
Limited community awareness, late and superficial institutional support, and cost-effectiveness issues paint a bleak future for Pre-Exposure Prophylaxis in the UK. On the opening day of the TasP PrEP Evidence Summit organised by IAPAC, Lord Fowler expressed his bemusement at the US attitude towards clean
Don’t we all know that popping pills is not the solution to all our problems? The writer reflects on his and other’s assumptions about the role of biomedical interventions in the control of the HIV epidemic. This blog’s title mirrors that of Jake Sobo’s “Why
2011, the year of PrEP. In less than 18 months 6 clinical trials investigating the potential use of HIV antiretrovirals (ARV) for the prevention of HIV acquisition have rocked the HIV prevention world. First it was the South African CAPRISA announcing in July 2010
A survey conducted by SIGMA Research is the first to provide some insights into the prospective attitude of gay and bisexual men towards PrEP in England following the release of the iPrEX study in 2010. Knowledge of PrEP, its acceptability, dosage preference and potential effects